These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 19322185)

  • 1. The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases.
    Ha H; Oh EY; Lee HB
    Nat Rev Nephrol; 2009 Apr; 5(4):203-11. PubMed ID: 19322185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAI-1 and kidney fibrosis.
    Ma LJ; Fogo AB
    Front Biosci (Landmark Ed); 2009 Jan; 14(6):2028-41. PubMed ID: 19273183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells.
    Gesualdo L; Ranieri E; Monno R; Rossiello MR; Colucci M; Semeraro N; Grandaliano G; Schena FP; Ursi M; Cerullo G
    Kidney Int; 1999 Aug; 56(2):461-70. PubMed ID: 10432384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Plasminogen activator inhibitor type 1: physiology and role in renal physiopathology].
    Rerolle JP; Vigneau C; Hertig A; Berrou J; Rondeau E
    Nephrologie; 2001; 22(1):5-13. PubMed ID: 11280040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis.
    Rerolle JP; Hertig A; Nguyen G; Sraer JD; Rondeau EP
    Kidney Int; 2000 Nov; 58(5):1841-50. PubMed ID: 11044203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation.
    Gupta KK; Donahue DL; Sandoval-Cooper MJ; Castellino FJ; Ploplis VA
    Sci Rep; 2017 Mar; 7(1):365. PubMed ID: 28336948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the plasminogen-plasmin system on hypertensive renal and cardiac damage.
    Knier B; Cordasic N; Klanke B; Heusinger-Ribeiro J; Daniel C; Veelken R; Hartner A; Hilgers KF
    J Hypertens; 2011 Aug; 29(8):1602-12. PubMed ID: 21610512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The renin-angiotensin-aldosterone system and fibrinolysis in progressive renal disease.
    Brown NJ; Vaughan DE; Fogo AB
    Semin Nephrol; 2002 Sep; 22(5):399-406. PubMed ID: 12224047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition.
    Pinsky DJ; Liao H; Lawson CA; Yan SF; Chen J; Carmeliet P; Loskutoff DJ; Stern DM
    J Clin Invest; 1998 Sep; 102(5):919-28. PubMed ID: 9727060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition.
    Oikawa T; Freeman M; Lo W; Vaughan DE; Fogo A
    Kidney Int; 1997 Jan; 51(1):164-72. PubMed ID: 8995730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of mouse models to study plasminogen activator inhibitor-1.
    Declerck PJ; Gils A; De Taeye B
    Methods Enzymol; 2011; 499():77-104. PubMed ID: 21683250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of PAI-1 expression by genetic polymorphisms. Impact on atherogenesis.
    Nordt TK; Lohrmann J; Bode C
    Thromb Res; 2001 Sep; 103 Suppl 1():S1-5. PubMed ID: 11567663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pathological role of increased expression of plasminogen activator inhibitor-1 in human or animal disorders.
    Yamamoto K; Saito H
    Int J Hematol; 1998 Dec; 68(4):371-85. PubMed ID: 9885437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling.
    Weisberg AD; Albornoz F; Griffin JP; Crandall DL; Elokdah H; Fogo AB; Vaughan DE; Brown NJ
    Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):365-71. PubMed ID: 15576638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pathophysiological relevance of PAI-1 in cardiovascular diseases and the development of monoclonal antibodies as PAI-1 inhibitors.
    Gils A
    Verh K Acad Geneeskd Belg; 2006; 68(3):179-98. PubMed ID: 16796017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?
    Sillen M; Declerck PJ
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin and vascular fibrinolytic balance.
    Vaughan DE
    Am J Hypertens; 2002 Jan; 15(1 Pt 2):3S-8S. PubMed ID: 11824873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001.
    Huber K; Christ G; Wojta J; Gulba D
    Thromb Res; 2001 Sep; 103 Suppl 1():S7-19. PubMed ID: 11567664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women.
    Brown NJ; Abbas A; Byrne D; Schoenhard JA; Vaughan DE
    Circulation; 2002 Jan; 105(3):304-9. PubMed ID: 11804984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldosterone and PAI-1: implications for renal injury.
    Brown NJ; Vaughan DE; Fogo AB
    J Nephrol; 2002; 15(3):230-5. PubMed ID: 12113592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.